Rhode Island Chronicle

Nasopharyngeal Carcinoma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Hoffmann-La Roche, Jiangsu HengRui Medicine, Qilu Pharma, Akeso

 Breaking News
  • No posts were found

Nasopharyngeal Carcinoma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Hoffmann-La Roche, Jiangsu HengRui Medicine, Qilu Pharma, Akeso

September 25
12:22 2023
Nasopharyngeal Carcinoma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Hoffmann-La Roche, Jiangsu HengRui Medicine, Qilu Pharma, Akeso
DelveInsight’s “Nasopharyngeal Carcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nasopharyngeal Carcinoma, historical and forecasted epidemiology as well as the Nasopharyngeal Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Nasopharyngeal Carcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nasopharyngeal Carcinoma, historical and forecasted epidemiology as well as the Nasopharyngeal Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Nasopharyngeal Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Nasopharyngeal Carcinoma Market Forecast

 

Some of the key facts of the Nasopharyngeal Carcinoma Market Report: 

  • The Nasopharyngeal Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Nasopharyngeal cancer affects men roughly three times more frequently than women, per the National Health Services (NHS)
  • Shah and Nagalli (2022) state that the rate ranges from a low of fewer than 1 cases per 100,000 people in non-endemic areas to a high of 25 to 50 cases per 100,000 men and 15 to 20 cases per 100,000 women in endemic regions
  • The predicted age-standardized incidence rate of nasopharyngeal cancer among males in 2018 was determined to be 0.84-1.6 per 100,000 for the United States and Japan, according to Chang et al.’s paper “The Evolving Epidemiology of Nasopharyngeal Carcinoma” (2021)
  • According to Globocan data, 1,898 incident cases of nasopharynx carcinoma occurred in the United States in 2020, making up around 133,354 cases worldwide
  • Key Nasopharyngeal Carcinoma Companies: Akesobio, Viracta Therapeutics, ProfoundBio, Ascentage Pharma, Novartis, Chia Tai Tianqing Pharma, Hoffmann-La Roche, Jiangsu HengRui Medicine, Qilu Pharma, Akeso, Bristol-Myers Squibb, Sanofi, BeiGene, Merck Sharp & Dohme LLC, Viracta Therapeutics, Inc., AstraZeneca, and others
  • Key Nasopharyngeal Carcinoma Therapies: Penpulimab, Nanatinostat + Valganciclovir, PRO1160, APG-5918, DKY709, TQB2618, Carboplatin/Cisplatin, Camrelizumab, QL1706, Zometa (zoledronic acid), Penpulimab, Nivolumab, Docetaxel, Tislelizumab, CC-486, Celgene, Gemcitabine, Nanatinostat, Gefitinib, and others
  • The Nasopharyngeal Carcinoma epidemiology based on gender analyzed that males are most commonly affected in the case of Nasopharyngeal Carcinoma
  • The Nasopharyngeal Carcinoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Nasopharyngeal Carcinoma pipeline products will significantly revolutionize the Nasopharyngeal Carcinoma market dynamics.

 

Nasopharyngeal Carcinoma Overview

The portion of the throat (nasopharynx) that connects the back of the nose to the back of the mouth is affected by a kind of head and neck cancer called nasopharyngeal carcinoma. Nasopharyngeal cancer is an undifferentiated squamous cell carcinoma that develops from the nasopharynx’s epithelium.

 

Get a Free sample for the Nasopharyngeal Carcinoma Market Report 

https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market

 

Nasopharyngeal Carcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Nasopharyngeal Carcinoma Epidemiology Segmentation:

The Nasopharyngeal Carcinoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Nasopharyngeal Carcinoma
  • Prevalent Cases of Nasopharyngeal Carcinoma by severity
  • Gender-specific Prevalence of Nasopharyngeal Carcinoma
  • Diagnosed Cases of Episodic and Chronic Nasopharyngeal Carcinoma

 

Download the report to understand which factors are driving Nasopharyngeal Carcinoma epidemiology trends @ Nasopharyngeal Carcinoma Epidemiology Forecast

 

Nasopharyngeal Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nasopharyngeal Carcinoma market or expected to get launched during the study period. The analysis covers Nasopharyngeal Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Nasopharyngeal Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Nasopharyngeal Carcinoma Therapies and Key Companies

  • Penpulimab: Akesobio
  • Nanatinostat + Valganciclovir: Viracta Therapeutics
  • PRO1160: ProfoundBio
  • APG-5918: Ascentage Pharma
  • DKY709: Novartis Pharmaceuticals
  • TQB2618: Chia Tai Tianqing Pharma
  • Carboplatin/Cisplatin: Hoffmann-La Roche
  • Camrelizumab: Jiangsu HengRui Medicine
  • QL1706: Qilu Pharma
  • Zometa (zoledronic acid): Novartis
  • Penpulimab: Akeso
  • Nivolumab: Bristol-Myers Squibb
  • Docetaxel: Sanofi
  • Tislelizumab: BeiGene
  • CC-486: Celgene
  • Gemcitabine: Merck Sharp & Dohme LLC
  • Nanatinostat: Viracta Therapeutics, Inc.
  • Gefitinib: AstraZeneca

 

Discover more about therapies set to grab major Nasopharyngeal Carcinoma market share @ Nasopharyngeal Carcinoma Treatment Market

 

Scope of the Nasopharyngeal Carcinoma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Nasopharyngeal Carcinoma Companies: Akesobio, Viracta Therapeutics, ProfoundBio, Ascentage Pharma, Novartis, Chia Tai Tianqing Pharma, Hoffmann-La Roche, Jiangsu HengRui Medicine, Qilu Pharma, Akeso, Bristol-Myers Squibb, Sanofi, BeiGene, Merck Sharp & Dohme LLC, Viracta Therapeutics, Inc., AstraZeneca, and others
  • Key Nasopharyngeal Carcinoma Therapies: Penpulimab, Nanatinostat + Valganciclovir, PRO1160, APG-5918, DKY709, TQB2618, Carboplatin/Cisplatin, Camrelizumab, QL1706, Zometa (zoledronic acid), Penpulimab, Nivolumab, Docetaxel, Tislelizumab, CC-486, Celgene, Gemcitabine, Nanatinostat, Gefitinib, and others
  • Nasopharyngeal Carcinoma Therapeutic Assessment: Nasopharyngeal Carcinoma current marketed and Nasopharyngeal Carcinoma emerging therapies
  • Nasopharyngeal Carcinoma Market Dynamics: Nasopharyngeal Carcinoma market drivers and Nasopharyngeal Carcinoma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Nasopharyngeal Carcinoma Unmet Needs, KOL’s views, Analyst’s views, Nasopharyngeal Carcinoma Market Access and Reimbursement 

 

To know more about Nasopharyngeal Carcinoma companies working in the treatment market, visit @ Nasopharyngeal Carcinoma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Nasopharyngeal Carcinoma Market Report Introduction

2. Executive Summary for Nasopharyngeal Carcinoma

3. SWOT analysis of Nasopharyngeal Carcinoma

4. Nasopharyngeal Carcinoma Patient Share (%) Overview at a Glance

5. Nasopharyngeal Carcinoma Market Overview at a Glance

6. Nasopharyngeal Carcinoma Disease Background and Overview

7. Nasopharyngeal Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Nasopharyngeal Carcinoma 

9. Nasopharyngeal Carcinoma Current Treatment and Medical Practices

10. Nasopharyngeal Carcinoma Unmet Needs

11. Nasopharyngeal Carcinoma Emerging Therapies

12. Nasopharyngeal Carcinoma Market Outlook

13. Country-Wise Nasopharyngeal Carcinoma Market Analysis (2019–2032)

14. Nasopharyngeal Carcinoma Market Access and Reimbursement of Therapies

15. Nasopharyngeal Carcinoma Market Drivers

16. Nasopharyngeal Carcinoma Market Barriers

17.  Nasopharyngeal Carcinoma Appendix

18. Nasopharyngeal Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories